期刊文献+

胰岛素样生长因子1与原发性高血压 被引量:3

Insulin - like growth factor 1 and essential hypertension
下载PDF
导出
摘要 目的:探讨原发性高血压病的发病机制。方法:对28例原发性高血压患者和16名正常人测定了血清胰岛素样生长因子1(IGF1),并与高血压分级进行了相关分析。结果:原发性高血压患者IGF1水平显著低于正常人(分别为26.22μg/L±20.23μg/L和48.02μg/L±33.43μ/L,P<0.05),且IGF1水平与临床分级呈负相关(=-0.437,P<0.05)。 结论:IGF1可能参与了原发性高血压的病理生理过程。 Objective: IGF1 in hypertensives was determined to investigate the possible mechanism of hypertension. Methods: The levels of serum IGF1 in 28 patients with essential hypertension and 16 normal individuals were determined and correlation analysis was done between them and clinical grading of hypertension. Results: IGF1 level in patients with essential hypertension (26.22μg/L±20.23μg/L) was significantly lower (P<0.05) than that in normal controls (48.02μg/L±33. 43/μg/L) and IGF1 level correlated negatively with clinical grading (r = -0.437, P<0.05). Conclusions; IGF1 is probably involved in the patho-physiological process of essential hypertension.
出处 《国外医学(心血管疾病分册)》 2002年第2期104-105,共2页
关键词 原发性高血压 胰岛素样生长因子1 发病机制 病理生理 Hypertension Mechanism Insulin-like growth factor 1
  • 相关文献

参考文献8

  • 1Ren J, Samson WK, Sowers JR. Insulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease. J Mol Cell Cardiol, 1999; 31(11): 2049~2061
  • 2刘力生.2004年中国高血压防治指南(实用本)[J].中华心血管病杂志,2004,32(12):1060-1064. 被引量:2620
  • 3Re, HER. Amino terminal sequences of two polypeptides from human serum with no-suppresible insulin-like and cellgrowth promoting activities. Proc Natl Acad Sci USA, 1976; 73: 4379~4381
  • 4Jiang X, Srinivasan SR, Dalferes ER Jr, et al. Plasma insulin-like growth factor 1 distribution and its relation to blood pressure in adolescents: the Bogalusa Heart Study. Am J Hypertens, 1997; 10(7 pt 1): 714~719
  • 5Ebensperger R, Acevedo E, Melendez J, et al. Selective increase in cardiac IGF1 in a rat model of ventricular hypertrophy. Biochem Biophys Res Commun, 1998; 243(1): 20~24
  • 6Boger RH, Skamira C, Bode-Boger SM, et al. Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone on patients with acquired growth hormone deficiency. A double-blind, placebo-controlled study. J Clin Invest, 1996; 98(12): 2706~2713
  • 7Leri A, Liu Y, Claudio PP, et al. Insulin-like growth factor1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol, 1999; 154(2): 567~580
  • 8Hasdai D, Rihal CS. Holmes DR Jr, et al. Insulin and insulin-like growth factor-1 cause coronary vasorelaxation in vitro. Hypertension, 1998; 32(2): 228~234

共引文献2619

同被引文献17

  • 1Ren J, Samson WK,Sowers JR. In sulin-like growth factor I as a cardiac hormone: physiological and pathophysiological implications in heart disease[ J]. J Mol Cell Cardiol, 1999,31 ( 11 ): 2649 - 2061.
  • 2Tofe I, Bonaa KH,Jenssen T. Insulin resistance in hypertension is associated with body fat rather than blood pressure [ J]. Hypertension,1998,32(1): 115 - 122.
  • 3Ebensperger R, Acevedo E, Melendez J, et al. Selective increase in cardliac IGF-1 in a rat model of ventricular hypertrophy[ J]. Bioehem Biophys Res Commun, 1998,243 ( 1 ): 20 - 24.
  • 4Leri A, Liu Y, Claudio PP, et al. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis[J]. Am J Pathol,1999,154(2) :567 - 580.
  • 5Hasdai D, Nielsen MF, Rizza RA, et al. Attenuated in vitro coronary arteriolar vasorelaxation to insulin-like growth factor I in experimental hypereholesterolemia[ J]. Hypertension, 1999,34( 1 ): 89 - 95.
  • 6Jalil JE, Ebensperger R, Me le ndez J, et al. Effects of antihypertensive treatment on cardiac IGF-1 during prevention of ventricular hypertrophy in the rt[J]. Life Sci,1999,64(18) :1603 - 1612.
  • 7Ebensperger R, Acevedo E, Melendez J, et al. Selective increase in cardiac IGF- 1 in a rat model of ventricular hypertrophy[ J]. Biochem Biophs Res Commun, 1998, 243 ( 1 ) :20-24.
  • 8Leri A, Liu Y, Claydio PP, et al. Insulin-like growth factor-1 in- dues mdmz and down-regulates p53, attenuating the myocyte rennin-an- giotensin system and stretch-mediated apoptosis [ J]. Am J Pathol, 1999, 154(2) :567-580.
  • 9Celinshi R, Graywa-eelinska A, Cholewiski W, et al. Relationship between plasma brain natriuretic peptide level and left ventricular systolic function in coronary artery disease[ J]. Pol Merkur Lekarski, 2005, 18 (105) : 291-294.
  • 10Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York heart association Class during the outpatient treatment of heart failure [ J ]. J Card Fail, 2002,8(2) :149-156.

引证文献3

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部